Rivaroxaban in patients with a recent acute coronary syndrome

Jessica L Mega; Eugene Braunwald; Stephen D Wiviott; Jean-Pierre Bassand; Deepak L Bhatt; Christoph Bode; Paul Burton; Marc Cohen; Nancy Cook-Bruns; Keith A A Fox; Shinya Goto; Sabina A Murphy; Alexei N Plotnikov; David Schneider; Xiang Sun; Freek W A Verheugt; C Michael Gibson; ATLAS ACS 2–TIMI 51 Investigators; Peer Grande

doi:10.1056/NEJMoa1112277

Rivaroxaban in patients with a recent acute coronary syndrome

Jessica L Mega, Eugene Braunwald, Stephen D Wiviott, Jean-Pierre Bassand, Deepak L Bhatt, Christoph Bode, Paul Burton, Marc Cohen, Nancy Cook-Bruns, Keith A A Fox, Shinya Goto, Sabina A Murphy, Alexei N Plotnikov, David Schneider, Xiang Sun, Freek W A Verheugt, C Michael Gibson, ATLAS ACS 2–TIMI 51 Investigators, Peer Grande

1840 Citations (Scopus)

Abstract

Acute coronary syndromes arise from coronary atherosclerosis with superimposed thrombosis. Since factor Xa plays a central role in thrombosis, the inhibition of factor Xa with low-dose rivaroxaban might improve cardiovascular outcomes in patients with a recent acute coronary syndrome.

Original language	English
Journal	New England Journal of Medicine
Volume	366
Issue number	1
Pages (from-to)	9-19
Number of pages	11
ISSN	0028-4793
DOIs	https://doi.org/10.1056/NEJMoa1112277
Publication status	Published - 2012

Keywords

Acute Coronary Syndrome
Aged
Anticoagulants
Cardiovascular Diseases
Double-Blind Method
Drug Administration Schedule
Factor Xa
Female
Hemorrhage
Humans
Incidence
Intracranial Hemorrhages
Kaplan-Meier Estimate
Male
Middle Aged
Morpholines
Secondary Prevention
Thiophenes

Access to Document

10.1056/NEJMoa1112277

Cite this

Mega, J. L., Braunwald, E., Wiviott, S. D., Bassand, J.-P., Bhatt, D. L., Bode, C., Burton, P., Cohen, M., Cook-Bruns, N., Fox, K. A. A., Goto, S., Murphy, S. A., Plotnikov, A. N., Schneider, D., Sun, X., Verheugt, F. W. A., Gibson, C. M., ATLAS ACS 2–TIMI 51 Investigators, & Grande, P. (2012). Rivaroxaban in patients with a recent acute coronary syndrome. New England Journal of Medicine, 366(1), 9-19. https://doi.org/10.1056/NEJMoa1112277

Mega, JL, Braunwald, E, Wiviott, SD, Bassand, J-P, Bhatt, DL, Bode, C, Burton, P, Cohen, M, Cook-Bruns, N, Fox, KAA, Goto, S, Murphy, SA, Plotnikov, AN, Schneider, D, Sun, X, Verheugt, FWA, Gibson, CM, ATLAS ACS 2–TIMI 51 Investigators & Grande, P 2012, 'Rivaroxaban in patients with a recent acute coronary syndrome', New England Journal of Medicine, vol. 366, no. 1, pp. 9-19. https://doi.org/10.1056/NEJMoa1112277

@article{83c74f094e1441c387f8675499a90357,

title = "Rivaroxaban in patients with a recent acute coronary syndrome",

abstract = "Acute coronary syndromes arise from coronary atherosclerosis with superimposed thrombosis. Since factor Xa plays a central role in thrombosis, the inhibition of factor Xa with low-dose rivaroxaban might improve cardiovascular outcomes in patients with a recent acute coronary syndrome.",

keywords = "Acute Coronary Syndrome, Aged, Anticoagulants, Cardiovascular Diseases, Double-Blind Method, Drug Administration Schedule, Factor Xa, Female, Hemorrhage, Humans, Incidence, Intracranial Hemorrhages, Kaplan-Meier Estimate, Male, Middle Aged, Morpholines, Secondary Prevention, Thiophenes",

author = "Mega, \{Jessica L\} and Eugene Braunwald and Wiviott, \{Stephen D\} and Jean-Pierre Bassand and Bhatt, \{Deepak L\} and Christoph Bode and Paul Burton and Marc Cohen and Nancy Cook-Bruns and Fox, \{Keith A A\} and Shinya Goto and Murphy, \{Sabina A\} and Plotnikov, \{Alexei N\} and David Schneider and Xiang Sun and Verheugt, \{Freek W A\} and Gibson, \{C Michael\} and \{ATLAS ACS 2–TIMI 51 Investigators\} and Peer Grande",

year = "2012",

doi = "10.1056/NEJMoa1112277",

language = "English",

volume = "366",

pages = "9--19",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "1",

}

TY - JOUR

T1 - Rivaroxaban in patients with a recent acute coronary syndrome

AU - Mega, Jessica L

AU - Braunwald, Eugene

AU - Wiviott, Stephen D

AU - Bassand, Jean-Pierre

AU - Bhatt, Deepak L

AU - Bode, Christoph

AU - Burton, Paul

AU - Cohen, Marc

AU - Cook-Bruns, Nancy

AU - Fox, Keith A A

AU - Goto, Shinya

AU - Murphy, Sabina A

AU - Plotnikov, Alexei N

AU - Schneider, David

AU - Sun, Xiang

AU - Verheugt, Freek W A

AU - Gibson, C Michael

AU - ATLAS ACS 2–TIMI 51 Investigators

AU - Grande, Peer

PY - 2012

Y1 - 2012

N2 - Acute coronary syndromes arise from coronary atherosclerosis with superimposed thrombosis. Since factor Xa plays a central role in thrombosis, the inhibition of factor Xa with low-dose rivaroxaban might improve cardiovascular outcomes in patients with a recent acute coronary syndrome.

AB - Acute coronary syndromes arise from coronary atherosclerosis with superimposed thrombosis. Since factor Xa plays a central role in thrombosis, the inhibition of factor Xa with low-dose rivaroxaban might improve cardiovascular outcomes in patients with a recent acute coronary syndrome.

KW - Acute Coronary Syndrome

KW - Aged

KW - Anticoagulants

KW - Cardiovascular Diseases

KW - Double-Blind Method

KW - Drug Administration Schedule

KW - Factor Xa

KW - Female

KW - Hemorrhage

KW - Humans

KW - Incidence

KW - Intracranial Hemorrhages

KW - Kaplan-Meier Estimate

KW - Male

KW - Middle Aged

KW - Morpholines

KW - Secondary Prevention

KW - Thiophenes

UR - https://www.scopus.com/pages/publications/84862907587

U2 - 10.1056/NEJMoa1112277

DO - 10.1056/NEJMoa1112277

M3 - Journal article

C2 - 22077192

SN - 0028-4793

VL - 366

SP - 9

EP - 19

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 1

ER -

Rivaroxaban in patients with a recent acute coronary syndrome

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this